Myriad Genetics, Onsite Women’s Health enter parntership

Myriad Genetics and Onsite Women’s Health announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk. The collaboration combines the strengths of Myriad’s hereditary breast cancer/risk assessment resources, MyRisk with RiskScore, and Onsite’s deep expertise in breast health services, including mammography and breast ultrasound. The program is expected to deliver personalized insights to better inform clinical care for the more than 400,000 patients Onsite serves nationwide. The new collaboration will help identify and screen younger patients who are at an increased risk for breast cancer. The American College of Radiology and the Society of Breast Imaging recommend that all women be evaluated for breast cancer risk no later than age 30 to help identify those at higher risk who would benefit from early screening. Current guidelines also state that women at high risk of breast cancer and/or genetically-based increased risk should begin annual screening breast MRI at age 25-30, and annual screening mammography at age 30.